Tetragenex has a platform of peptides which have shown activity in the treatment of CNS diseases. Nemifitide, the company’s lead compound, initially entered human clinical trials in the late 1990’s. Twelve human clinical trials have been conducted with Nemifitide for various types of depression. Nemifitide has shown a rapid and robust onset of action with lasting benefits of approximately four to six months following treatment. Nemifitide is well tolerated, without any current evidence of significant side effects as compared to the current drugs that are used in the treatment of major depressive disorder. Tetragenex believes that Nemifitide is active in refractory or treatment resistant patients. Treatment resistant patients, who represent approximately 5 to 10 percent of the overall patient population suffering from depression, are very difficult to treat because they have failed to respond to several of the current therapies on the market. Nemifitide is currently administered through subcutaneous injection and is given intermittently with 10 to 12 doses over two weeks.
Due to the prohibitively expensive and time consuming requirements for a full phase three and registration program in the U.S. , Tetragenex Pharmaceuticals has released it's compound to Tetragenex Medical Tourism, LLC, giving the LLC the immediate ability to proceed with the program in Guatemala, as well as pursue other relationships in other countries to service other parts of the word. Nemifitide will likely never be available in the United States. Based on the strong development of Nemifitide, the LLC believes it will be able to attract other relationship in Eastern Europe, the Far East and Asia to duplicate what it has achieved in Guatemala.
